12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Wednesday's pre-market session, 12 health care stocks experienced significant price movements. Gainers included Advanced Health, Ocean Biomedical, LumiraDx, Regulus Therapeutics, Cardio Diagnostics Hldgs, and Fusion Pharmaceuticals. Losers were Oncorus, Navidea Biopharmaceutical, Stoke Therapeutics, Celularity, T2 Biosystems, and Atreca.
June 21, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Advanced Health's stock increased by 143.2% to $1.8 during Wednesday's pre-market session, with a market cap of $50.4 million.
Advanced Health's stock increased significantly by 143.2% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Cardio Diagnostics Hldgs' shares moved upwards by 15.32% to $1.43 during Wednesday's pre-market session, with a market cap of $14.2 million.
Cardio Diagnostics Hldgs' shares increased by 15.32% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Fusion Pharmaceuticals' shares rose 14.31% to $4.95 during Wednesday's pre-market session, with a market cap of $340.9 million.
Fusion Pharmaceuticals' shares rose by 14.31% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
LumiraDx's stock rose 27.42% to $0.45 during Wednesday's pre-market session, with a market cap of $142.0 million.
LumiraDx's stock rose by 27.42% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ocean Biomedical's stock rose 38.34% to $7.36 during Wednesday's pre-market session, with a market cap of $250.3 million.
Ocean Biomedical's stock rose by 38.34% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regulus Therapeutics' shares rose 18.97% to $1.63 during Wednesday's pre-market session, with a market cap of $31.7 million.
Regulus Therapeutics' shares rose by 18.97% in the pre-market session, indicating strong investor interest and a potential positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Atreca's shares declined by 12.3% to $0.99 during Wednesday's pre-market session, with a market cap of $38.8 million.
Atreca's shares declined by 12.3% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Celularity's stock declined by 12.95% to $0.71 during Wednesday's pre-market session, with a market cap of $127.3 million.
Celularity's stock declined by 12.95% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Navidea Biopharmaceutical's stock decreased by 14.12% to $0.09 during Wednesday's pre-market session, with a market cap of $3.2 million.
Navidea Biopharmaceutical's stock decreased by 14.12% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Oncorus' shares fell 50.2% to $0.06 during Wednesday's pre-market session, with a market cap of $1.5 million.
Oncorus' shares fell by 50.2% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Stoke Therapeutics' stock decreased by 13.17% to $12.0 during Wednesday's pre-market session, with a market cap of $530.2 million.
Stoke Therapeutics' stock decreased by 13.17% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
T2 Biosystems' shares declined by 12.4% to $0.07 during Wednesday's pre-market session, with a market cap of $1.7 million.
T2 Biosystems' shares declined by 12.4% in the pre-market session, indicating a lack of investor interest and a potential negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100